Member Info for inanaco

TF, i suggest you study insider trading laws, they protect shareholders, so trying to use one comment from Ivy to suggest it supersedes another is basically stupid, as the first statement clearly disrupts.

Its not about what the political position of tommy Robinson is about, its about the way he goes about it which is the interference in the way the law operates

Insider Rules are to protect US ... shareholders

Just to Highlight ........Ivy made this statement

"""""If they make the mistake again imo of retreating into their shell and putting up barriers and refusing to answer genuine questions or hiding behind protocols and/or bad body language as they did to a large extent in 2015 then I fear the reaction will not be good."""""

Under Insider Trading Rules None of these questions in 2015 asked could be answered

You are delusional to expect the BOD to answer any question that is price sensitive, they go to prison NOT YOU ... strikes me you are going there as a trouble maker ... rather than to listen and absorb .. you just seem to think because you have bought a few shares that some how the Directors work for you, they don't they work on behalf of all shareholders, and act accordingly .. I am afraid its the 51% that have the power and they are backing Scancell
How many times do we have to have this discussion ...
would you like a reprint of your history on this subject. ?
You would be better served joining Tommy Robinson ..

we ... ? you mean they

put a value on that IP ... can you solve the Irish Backstop

Are you running any portion of the scib1 combo trial in the UK ?

are you preparing SCIB2 trial with the Ichor Gun

can you solve the Irish Backstop

you can explain to the BOD .. maybe easier

yes crumbs but chart also shows preclinical complete ?

i suggest that new immuno bodies could be developed using nanovesicle, not existing constructs

trigrid 2 is approved in Europe ... why would you revert to trigrid 1

why would Ichor not help with this issue ? your post makes little sense

ask the question at the AGM ... pretty sure scib2 is ichor

8mg is not needed in the adjuvant setting if you read the results

the discomfort is actually the adjuvant ..

very complicated change of direction

why spend another 5 years developing a Nanovesicle form of immunobody ? when we have one that works.

simple take the jab or die ..

spend the money on Moditope ..

we have a full licence to use the equipment Crumbs, so in effect it is ours ... for that particular use

lets wait for next week, other wise we will be discussing the back stop to the back stop ...

what we do know, one regulatory regime has approved its use ... which would also include the vaccine cartridge

Yawn

are you going ?

no i won't be going, way to many questions asked that cannot be answered because of insider rules. the old days consisted of about 10 shareholders ... not the 100 that turn up now. so at best i might get one question in for a 6 hour round trip .. rather use that money to buy shares, as i don't need to add to my understanding as the share price is so under valued, ie. enough information in the market to warrant a buy ...

well Crumbs the Scientist in Scancell are still working

SCIB2 toxicology etc

Modi2

Clycans

so its not really burning through the cash is it ? as this work was in the budget and the interest on £10m would cover the none science executive wages for a month or two

well its yet another buying opportunity .. Scancell is being revalued for nothing more than Time ... and its a minor problem that is not even in Scancells hands

Scancell could just run the trials in the UK, but how long would that take to recruit sites and get folks up to speed.

However the Sites selected that have joined the program in the US are top of the tree ...i would say more value in the market place if its signed of by the US investigators .. Its the worlds biggest and wealthiest market

Ichor Tri -Grid 2 is now in trial in Europe already and been used in Patients since June .. The Trial has not Halted

Robert Bernard, Ichor Founder and CEO, stated, “We are very pleased to be supporting the development of immunotherapies for patients suffering from chronic hepatitis B infection. With the start of this first clinical trial utilizing Ichor’s next generation TriGrid System, Ichor and its many partners enter an exciting time with the initiation of multiple additional clinical studies in oncology and chronic viral infection anticipated by the end of this year. Furthermore, Ichor’s device technology is now well-positioned to provide a pathway to commercialization for novel nucleic acid-based product candidates in both the prophylactic and therapeutic setting, including the expanding field of personalized medicine.”